<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Anaphylaxis</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->2/24/2012</div></div><div class="card__content"><h1 id="anaphylaxis">Anaphylaxis</h1>
<p><strong>Definition</strong>: A serious allergic reaction that is rapid in onset and might cause death</p>
<p><strong>Mechanism</strong>: IgE-mediated immune reaction</p>
<p><strong>Pearl</strong>: Hypotension is NOT required to diagnose anaphylaxis.</p>
<p><strong>Triggers</strong>: Almost any food, allergens, or medications can be a trigger.</p>
<p><strong>Common culprits</strong>:</p>
<ul>
<li>Antibiotics (especially beta-lactams)</li>
<li>NSAIDs</li>
<li>Peanuts</li>
<li>Shellfish</li>
</ul>
<p><strong>Organ involvement</strong>: </p>
<ul>
<li>Skin 80-90%</li>
<li>Respiratory 70%</li>
<li>Gastrointestinal 45%</li>
<li>Cardiovascular 45%</li>
<li>Central nervous system 15%</li>
</ul>
<p><strong>Biphasic anaphylaxis pattern</strong>: 2nd flare may occur despite trigger removed (typically within 72 hours of onset)</p>
<h2 id="diagnostic-criteria">Diagnostic criteria</h2>
<blockquote>
<p>Highly likely if <strong>1 or 3 criteria</strong> fulfilled per 2nd National Institute of Allergy and ID/Food Allergy and Anaphylaxis Network</p>
</blockquote>
<ol>
<li>Acute onset (min-several hrs), involving skin, mucosa, or both (hives, flushing, pruritis, angioedema) AND at least 1 of the following:<ul>
<li>Respiratory compromise: shortness of breath, wheezing, stridor, hypoxemia, reduced PEF</li>
<li>Reduced BP or associated sx of end-organ dysfunction: hypotonia, syncope, incontinence</li>
</ul>
</li>
<li>Two or more of the following that occur rapidly after exposure to likely allergen:<ul>
<li>Involvement of skin-mucosal tissue: hives, itching, flushing</li>
<li>Respiratory compromise: shortness of breath, wheezing, stridor, hypoxema, reduced PEF</li>
<li>Reduced BP or associated dx: hypotonia, syncope, incontinence</li>
<li>Persistent GI sx: cramping, abdominal pain, vomiting</li>
</ul>
</li>
<li>Reduced BP after exposure to known allergen<ul>
<li>Infants/children: Low SBP (age specific) or &gt; 30% decrease in SBP<ul>
<li>Age 1 mo - 1 yr: SBP &lt; 70 mmHg</li>
<li>Age 1 yr - 10 yr: SBP &lt; 70 mmHg + [2 x age]</li>
</ul>
</li>
<li>Adults: SBP &lt;90 mmHg or &gt;30% decrease in person&#39;s baseline</li>
</ul>
</li>
</ol>
<h2 id="ed-management">ED management</h2>
<ul>
<li>Supine position, ABCs</li>
<li><strong>IM <span class="drug">epinephrine</span> STAT</strong>. Repeat every 5-15 min if refractory<ul>
<li>0.3-0.5 mg for adults = 0.3-0.5 mL 0f 1:1000 concentration of epinephrine</li>
<li>0.15 mg for patient wt &lt; 30 kg</li>
<li><strong>IM injection into lateral thigh</strong> - quickest absorption centrally</li>
</ul>
</li>
<li>IV fluids 2 liters</li>
<li>H1 antagonist (eg. <span class="drug">diphenhydramine</span>)</li>
<li>H2 antagonist (eg. <span class="drug">ranitidine</span>)</li>
<li>Glucocorticoids (eg. <span class="drug">methylprednisolone</span>)<ul>
<li>2017 meta-analysis: Unlikely prevents biphasic anaphylactic reaction [Alqurashi]</li>
</ul>
</li>
<li><span class="drug">Albuterol</span> (beta-agonist) nebulizer for wheezing/lower airway obstruction</li>
<li>Consider: <span class="drug">Glucagon</span> 3.5-5 mg IV if refractory to epinephrine and on beta-blockers</li>
<li>If discharging patient home after observation, <strong>prescribe <span class="drug">epinephrine pen</span></strong></li>
</ul>
<h2 id="references">References</h2>
<ul>
<li>Alqurashi W, Ellis AK. Do Corticosteroids Prevent Biphasic Anaphylaxis? J
Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1194-1205. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/28888249">Pubmed</a>]</li>
<li>Arnold JJ, Williams PM. Anaphylaxis: recognition and management. Am Fam Physician. 2011;84(10):1111-8. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22085665">PubMed</a>]</li>
<li>Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S161-81. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20176258">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"anaphylaxis","title":"Anaphylaxis","authors":["Michelle Lin, MD"],"categories":[{"slug":"allergy-immunology","name":"Allergy-Immunology"}],"created":"2012/02/24","updated":"2017/02/13","body":"# Anaphylaxis\n\n**Definition**: A serious allergic reaction that is rapid in onset and might cause death\n\n**Mechanism**: IgE-mediated immune reaction\n\n**Pearl**: Hypotension is NOT required to diagnose anaphylaxis.\n\n**Triggers**: Almost any food, allergens, or medications can be a trigger.\n\n**Common culprits**:\n\n* Antibiotics (especially beta-lactams)\n* NSAIDs\n* Peanuts\n* Shellfish\n\n**Organ involvement**: \n\n* Skin 80-90%\n* Respiratory 70%\n* Gastrointestinal 45%\n* Cardiovascular 45%\n* Central nervous system 15%\n\n**Biphasic anaphylaxis pattern**: 2nd flare may occur despite trigger removed (typically within 72 hours of onset)\n\n## Diagnostic criteria\n\n\u003e Highly likely if **1 or 3 criteria** fulfilled per 2nd National Institute of Allergy and ID/Food Allergy and Anaphylaxis Network\n\n1. Acute onset (min-several hrs), involving skin, mucosa, or both (hives, flushing, pruritis, angioedema) AND at least 1 of the following:\n   * Respiratory compromise: shortness of breath, wheezing, stridor, hypoxemia, reduced PEF\n   * Reduced BP or associated sx of end-organ dysfunction: hypotonia, syncope, incontinence\n2. Two or more of the following that occur rapidly after exposure to likely allergen:\n   * Involvement of skin-mucosal tissue: hives, itching, flushing\n   * Respiratory compromise: shortness of breath, wheezing, stridor, hypoxema, reduced PEF\n   * Reduced BP or associated dx: hypotonia, syncope, incontinence\n   * Persistent GI sx: cramping, abdominal pain, vomiting\n3. Reduced BP after exposure to known allergen\n   * Infants/children: Low SBP (age specific) or \u003e 30% decrease in SBP\n     * Age 1 mo - 1 yr: SBP \u0026lt; 70 mmHg\n     * Age 1 yr - 10 yr: SBP \u0026lt; 70 mmHg + \\[2 x age]\n   * Adults: SBP \u0026lt;90 mmHg or \u003e30% decrease in person's baseline\n\n## ED management\n\n* Supine position, ABCs\n* **IM \u003cspan class=\"drug\"\u003eepinephrine\u003c/span\u003e STAT**. Repeat every 5-15 min if refractory\n  * 0.3-0.5 mg for adults = 0.3-0.5 mL 0f 1:1000 concentration of epinephrine\n  * 0.15 mg for patient wt \u0026lt; 30 kg\n  * **IM injection into lateral thigh** - quickest absorption centrally\n* IV fluids 2 liters\n* H1 antagonist (eg. \u003cspan class=\"drug\"\u003ediphenhydramine\u003c/span\u003e)\n* H2 antagonist (eg. \u003cspan class=\"drug\"\u003eranitidine\u003c/span\u003e)\n* Glucocorticoids (eg. \u003cspan class=\"drug\"\u003emethylprednisolone\u003c/span\u003e)\n  * 2017 meta-analysis: Unlikely prevents biphasic anaphylactic reaction \\[Alqurashi]\n* \u003cspan class=\"drug\"\u003eAlbuterol\u003c/span\u003e (beta-agonist) nebulizer for wheezing/lower airway obstruction\n* Consider: \u003cspan class=\"drug\"\u003eGlucagon\u003c/span\u003e 3.5-5 mg IV if refractory to epinephrine and on beta-blockers\n* If discharging patient home after observation, **prescribe \u003cspan class=\"drug\"\u003eepinephrine pen\u003c/span\u003e**\n\n## References\n\n* Alqurashi W, Ellis AK. Do Corticosteroids Prevent Biphasic Anaphylaxis? J\n  Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1194-1205. [[Pubmed](https://www.ncbi.nlm.nih.gov/pubmed/28888249)]\n* Arnold JJ, Williams PM. Anaphylaxis: recognition and management. Am Fam Physician. 2011;84(10):1111-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22085665)]\n* Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S161-81. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20176258)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"anaphylaxis"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>